Monday, February 18, 2019

Obesity Journal- Lupine Publishers



Since 2010, the American Diabetes Association has endorsed both HbA1C (A1C) and fasting plasma glucose (FPG) to determine diabetes risk. Given the discordance between classifications based on FPG and A1C and higher A1C levels among African Americans (AAs) than whites, we sought to examine the prevalence of normoglycemia, prediabetes, and diabetes among a community sample of adult AAs (n=704) screened for enrollment in a randomized Diabetes Prevention Program (DPP). We conducted a retrospective analysis to estimate the degree of discordance between risk categories based on FPG and A1C and examine the risk factors that predicted A1C and FPG levels. To determine differential effects on risk categories defined using FPG and A1C, we examined the effects of the program on the measures at 12 weeks post-intervention among the intervention arm participants.

The tests revealed different prevalence levels at baseline: A1C, 36.2% normoglycemia, 52% prediabetes and 11.8% diabetes; FPG, 81.1%, 16.8%, and 2%, respectively. There was discordance among A1C and FPG and among the risk categories (p<0.001). Both final regression models included age and waist circumference as predictors. For FPG, additional predictors were family history of diabetes and male gender. Post intervention, only those classified in the prediabetes category defined in terms of either test demonstrated intervention effects. Screening test choice results in different sample composition; both A1C and FPG respond to intervention effects among individuals classified in the prediabetes group only. These results have implications for research and clinical practice.


For more Lupine publishers open access journals please visit our website

For more Obesity Journal please click here




No comments:

Post a Comment

Lupine Publishers| Semaglutide versus liraglutide for treatment of obesity

  Lupine Publishers| Journal of Diabetes and Obesity Abstract Background: Once weekly (OW) semaglutide is a glucagon-like peptide...